GALE antibody - 100 µg
Host : Rabbit
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: UDP-galactose-4-epimerase
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 36 kDa
Uniprot: Q14376
Gene id: 2582
Background: This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified.
Field of research: Metabolism
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months (Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC, IF
Dilution: WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:10 - 1:100
Target: GALE
Purification: Immunogen affinity purified
Reactivity: Human, Mouse, Rat
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: UDP-galactose-4-epimerase
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 36 kDa
Uniprot: Q14376
Gene id: 2582
Background: This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified.
Field of research: Metabolism
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months (Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC, IF
Dilution: WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:10 - 1:100
Target: GALE
Purification: Immunogen affinity purified
Reactivity: Human, Mouse, Rat